New blood test could track Alzheimer's treatment in real time

NCT ID NCT07688460

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This phase 4 trial tests lecanemab, an antibody treatment for Alzheimer's disease, in 100 people with mild cognitive impairment or mild Alzheimer's dementia. Participants receive lecanemab infusions every two weeks for 18 months. The study also evaluates a new blood test that uses a special gold electrode to measure Alzheimer's-related proteins, aiming to see if it can reliably track how well the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Lecanemab
What this could lead to
If successful, this study could show that lecanemab slows cognitive decline in early Alzheimer's and validate a new blood test to monitor treatment response.
What could go wrong
This is a single-arm, open-label study with no placebo group, so results may be less reliable. Lecanemab can cause brain swelling or bleeding, and the new blood test is still experimental.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    RECRUITING

    Yiwu, Zhejiang, 322000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.